Abstract
AbstractHuntington’s Disease (HD) is a severe neurodegenerative disorder caused by expansion of the CAG trinucleotide repeat tract in the huntingtin gene. Inheritance of expanded CAG repeats is needed for HD manifestation, but further somatic expansion of the repeat tract in non-dividing cells, particularly striatal neurons, hastens disease onset. Called somatic repeat expansion, this process is mediated by the mismatch repair (MMR) pathway. Among MMR components identified as modifiers of HD onset, MutS Homolog 3 (MSH3) has emerged as a potentially safe and effective target for therapeutic intervention. Here, we identify fully chemically modified short interfering RNA (siRNA) that robustly silence MSH3in vitroandin vivo. When synthesized in a di-valent scaffold, siRNA-mediated silencing of MSH3 effectively blocked CAG repeat expansion in striatum of two HD mouse models without impacting tumor-associated microsatellite instability. Our findings establish a novel paradigm for treating patients with HD and other repeat expansion diseases.One Sentence SummarySilencing MSH3 in the CNS of two models of Huntington’s disease using di-valent siRNA blocks disease-accelerating somatic expansion of CAG repeats.
Publisher
Cold Spring Harbor Laboratory
Reference66 articles.
1. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities;Nature Reviews Neurology,2020
2. Therapies targeting DNA and RNA in Huntington’s disease;The Lancet Neurology,2017
3. Potential disease-modifying therapies for Huntington’s disease: lessons learned and future opportunities;The Lancet Neurology,2022
4. R. Ghosh , S. J. Tabrizi , in Polyglutamine Disorders, C. Nóbrega, L. Pereira de Almeida , Eds. (Springer International Publishing, Cham, 2018), pp. 1–28.
5. Huntington's disease: a clinical review